Pulmonx Co. (NASDAQ:LUNG) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Pulmonx Co. (NASDAQ:LUNG) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $12.75.

LUNG has been the subject of several research reports. Citigroup began coverage on shares of Pulmonx in a research report on Monday, March 10th. They issued a “buy” rating for the company. Jefferies Financial Group began coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a “buy” rating for the company. Morgan Stanley assumed coverage on Pulmonx in a research report on Monday, March 10th. They issued an “equal weight” rating on the stock. Finally, D. Boral Capital started coverage on Pulmonx in a research report on Monday, March 10th. They set a “buy” rating and a $17.00 target price for the company.

Pulmonx Stock Up 0.6 %

NASDAQ LUNG opened at $5.20 on Tuesday. The stock’s 50 day simple moving average is $6.81 and its 200 day simple moving average is $6.60. Pulmonx has a one year low of $4.15 and a one year high of $10.01. The firm has a market cap of $209.28 million, a PE ratio of -3.61 and a beta of 0.61. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The company had revenue of $23.77 million for the quarter, compared to analysts’ expectations of $22.29 million. As a group, sell-side analysts forecast that Pulmonx will post -1.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $7.85, for a total transaction of $157,000.00. Following the sale, the director now owns 991,974 shares of the company’s stock, valued at approximately $7,786,995.90. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Mehul Joshi sold 14,384 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.12, for a total value of $102,414.08. Following the completion of the transaction, the chief financial officer now directly owns 113,986 shares of the company’s stock, valued at approximately $811,580.32. The trade was a 11.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 145,660 shares of company stock worth $1,128,484. Insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Pulmonx

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in Pulmonx during the 4th quarter worth approximately $43,000. R Squared Ltd bought a new stake in shares of Pulmonx during the fourth quarter worth $46,000. 272 Capital LP acquired a new stake in shares of Pulmonx during the third quarter worth $48,000. ProShare Advisors LLC bought a new stake in Pulmonx in the 4th quarter valued at $72,000. Finally, Stifel Financial Corp acquired a new position in Pulmonx in the 4th quarter worth $81,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.